ストックスクリーナーアプリを入手
21.52
5.45%
-1.24
アフターアワーズ：
21.54
0.02
+0.09%
前日終値:
$22.76
開ける：
$23.12
24時間の取引高:
158.60K
Relative Volume:
0.59
時価総額：
$678.43M
収益：
-
当期純損益:
$-29.59M
株価収益率:
-16.88
EPS:
-1.275
ネットキャッシュフロー:
$-18.35M
1週間 パフォーマンス:
+11.44%
1か月 パフォーマンス:
+17.02%
6か月 パフォーマンス:
+165.35%
1年 パフォーマンス:
+209.20%
1日の値動き範囲:
$21.21
$23.12
1週間の範囲:
$19.00
$23.12
52週間の値動き範囲:
$5.55
$29.27
Nuvectis Pharma Inc Stock (NVCT) Company Profile
名前
Nuvectis Pharma Inc
セクター
電話
360-837-7232
住所
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
21.52 | 616.01M | 0 | -29.59M | -18.35M | -1.275 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-02 | 開始されました | Maxim Group | Buy |
| 2025-03-17 | 開始されました | Laidlaw | Buy |
| 2022-07-13 | 開始されました | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc (NVCT) 最新ニュース
Nuvectis Pharma Inc (NVCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nuvectis Pharma Inc (NVCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NVCT|Nuvectis Pharma Inc|Price:19.530|Chg%:+0.220 - TradingKey
NVCT|Nuvectis Pharma Inc|Price:19.310|Chg%:-0.840 - TradingKey
Nuvectis Pharma Inc (NVCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nuvectis Pharma Inc (NVCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nuvectis Pharma Inc (NVCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nuvectis Pharma Inc (NVCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nuvectis Pharma Inc (NVCT) Cash Flow - TradingKey
TradingKey - TradingKey
Maxim Group Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $39 - Moomoo
China approves Nuvectis’ ciprocopan for blood disorder PNH - Investing.com UK
Pantginis Reiterates Buy on Nuvectis, Citing Ciprocopan Approval and Pipeline Diversification; Price Target Maintained at $39 - TipRanks
Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor - TipRanks
Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor - Benzinga
Correction: Nuvectis Announces Marketing Approval of Ciprocopan in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors - Investing News Network
Nuvectis Pharma Announces First Global Approval of Once-Daily Oral Complement Factor B Inhibitor Ciprocopan in China for PNH - Quiver Quantitative
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors - GlobeNewswire
China approves ciprocopan, first oral once-dail... - Pluang
China approves Nuvectis’ ciprocopan for blood disorder PNH By Investing.com - Investing.com Australia
Nuvectis Pharma receives China approval for Ciprocopan to treat PNH in patients not given complement inhibitors - Traders Union
Nuvectis Drug Reached 12 g/dL in 59.5% of PNH Patients - Stock Titan
Nuvectis' NXP100 Just Achieved The First Marketing Approval Ever For A Once-Daily Oral Factor B Inhibitor - Menafn
NVCT Q1 2026 Earnings: EPS Beat Estimates as Company Advances PipelineEarnings Yield Analysis - dars.gov.et
Nuvectis Pharma Prices $100 Million Public Offering to Advance Pipeline - citybuzz -
Nuvectis Pharma Targets a $9.8 Billion Oral PNH Market With Late-Stage NXP100 - t.co
Wall Street analysts see a 61.46% upside in Nuvectis Pharma (NVCT): Can the stock really move this high? - MSN
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data - Cantech Letter
Nuvectis Pharma expands into rare diseases with... - Pluang
Wall Street Wire: StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data - FinanzNachrichten.de
How (NVCT) Movements Inform Risk Allocation Models - Stock Traders Daily
Catalyst watch: SpaceX initiations, Sun Valley Conference, PepsiCo earnings - MSN
NVCT Stock Price, Quote & Chart - ChartMill
Nuvectis Pharma’s NXP900 Combo Trial Adds Fresh Momentum to NVCT in EGFR Lung Cancer - TipRanks
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush - TipRanks
Nuvectis Pharma Inc (NVCT) News, Articles, Events & Latest Updates - Stocktwits
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? - Yahoo Finance
Roth MKM Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Nuvectis Pharma Price Target Raised to $33.00/Share From $20.00 by Roth Capital - Moomoo
Roth Capital raises Nuvectis target to $33 - scanx.trade
Roth MKM Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $33 - Moomoo
An Insider Of Nuvectis Pharma Picks Up 1.5% More Stock - 富途牛牛
Trading Systems Reacting to (NVCT) Volatility - Stock Traders Daily
What makes Nuvectis Pharma, Inc. (NVCT) a strong momentum stock: Buy now? - MSN
Nuvectis Pharma announces public share offering to support drug programs - MSN
Nuvectis Pharma Announces Major Public Equity Offering - The Globe and Mail
Insider Buying: Ron Bentsur Acquires Additional Shares of Nuvect - GuruFocus
Nuvectis Pharma CEO Ron Bentsur buys $250,000 in company stock By Investing.com - Investing.com Nigeria
Nuvectis Pharma CEO Ron Bentsur buys $250,000 in company stock - Investing.com
[Form 4] Nuvectis Pharma, Inc. Insider Trading Activity - Stock Titan
Nuvectis Pharma Inc (NVCT) 財務データ
収益
当期純利益
現金流量
EPS
Nuvectis Pharma Inc (NVCT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| BENTSUR RON | Chairman & CEO |
Jun 30 '26 |
Buy |
20.00 |
12,500 |
250,000 |
3,688,424 |
| BENTSUR RON | Chairman & CEO |
Nov 05 '25 |
Buy |
5.72 |
5,000 |
28,600 |
3,525,924 |
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):